Xyrem Settlement Gets Green Light

Law360, New York (July 13, 2007, 12:00 AM EDT) -- A federal judge on Friday approved Jazz Pharmaceuticals Inc.'s $20 million settlement with the federal government over an investigation into the promotion of Xyrem, a narcolepsy treatment containing oft-abused GHB, by Orphan Medical Inc., now a subsidiary of Jazz.

GHB, the popular name for gamma-hydroxybutyrate, is a powerful and almost immediate central nervous system depressant that is often illegally used for recreation. The Health and Human Services Department has classified it as a date rape drug.

Jazz' settlement figure, approved by Judge Eric Vitaliano of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.